Posted by Michael Wonder on 17 Oct 2023
NorthSea Therapeutics receives FDA rare paediatric disease designation for SEFA-6179 for the treatment of intestinal failure-associated liver disease
17 October 2023 - Rare paediatric disease designation underscores critical need for novel therapies to address IFALD.
NorthSea Therapeutics today announced that one of its novel structural engineered fatty acids, SEFA-6179, has been granted rare paediatric disease designation by the US FDA for the treatment of intestinal failure-associated liver disease.
